Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Year-End Submissions Total 17, Including Four From Aventis

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Aventis was the most prominent participant in the year-end NDA filing rush, submitting four applications: two new molecular entities, a vaccine and a new formulation.

You may also be interested in...

La Jolla Riquent SPA

La Jolla initiates a Phase IV trial of its pending lupus agent Riquent (abetimus) to support full approval, the firm announces Aug. 2. The randomized, double-blind, placebo-controlled study was agreed to under the special protocol assessment process and will meet FDA's accelerated approval requirement for a confirmatory postmarketing study. La Jolla said the trial design has "several enhancements" compared to prior Riquent studies, "including twice as many patients receiving Riquent compared with placebo, increased patient enrollment of approximately 500 to 600 patients, more control of immunosuppressive drugs at baseline, higher doses of Riquent in some treatment groups, and 12-month treatment duration for each patient." The primary endpoint is time to renal flare. The study will continue for "several years." Riquent's PDUFA date is Oct. 16 (1Pharmaceutical Approvals Monthly Jan 1, 2004, p. 15)...

Alvesco Side Effect Profile May Give Edge Among Corticosteroids

Aventis and Altana are hoping Alvesco’s similar rate of oropharyngeal side effects to placebo will help the agent penetrate the inhaled corticosteroid market.

Genta/Aventis Genasense Rolling NDA Submission Will Be Completed In Q4

Genta’s Phase III Genasense results should be enough to gain FDA approval for treatment of malignant melanoma despite the lack of a statistically significant improvement in survival in the intent to treat population, the firm told a Sept. 10 conference call.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts